The Kable

The Kable

Share this post

The Kable
The Kable
💉 A potential threat to the world's generics supply; Pfizer, BioNTech's promising combo vaccine; Sanofi's spin-off of its consumer health business
Copy link
Facebook
Email
Notes
More
Friday Kable

💉 A potential threat to the world's generics supply; Pfizer, BioNTech's promising combo vaccine; Sanofi's spin-off of its consumer health business

#459 | Malarial protein discoveries; A phage diet for cells; Migraines in your genes

Ria's avatar
Vinod's avatar
Ria
and
Vinod
Oct 27, 2023
∙ Paid

Share this post

The Kable
The Kable
💉 A potential threat to the world's generics supply; Pfizer, BioNTech's promising combo vaccine; Sanofi's spin-off of its consumer health business
Copy link
Facebook
Email
Notes
More
Share

Hello, and welcome to our free Friday edition of The Kable. Today, we kick things off with good news on the respiratory virus vaccine front. Pfizer and BioNTech have announced positive results from phase 1/2 studies of their mRNA-based combo vaccine, which generated robust immune responses to influenza A, influenza B, and SARS-CoV-2 strains. A phase 3 t…

Keep reading with a 7-day free trial

Subscribe to The Kable to keep reading this post and get 7 days of free access to the full post archives.

Already a paid subscriber? Sign in
© 2025 The Kable
Privacy ∙ Terms ∙ Collection notice
Start writingGet the app
Substack is the home for great culture

Share

Copy link
Facebook
Email
Notes
More